Pharmaceuticals and Global Health

Inequalities and Innovation in the 21st Century

• Levels of funding• Nature of funding

• Product development partnerships• Innovative developing countries• What has been delivered?

• High risk R&D, long development / short political timelines

• Targeted funding to match R&D needs

• Diversification of funding

Improved sustainabilityin global health R&D

Enabling health impact in developing countries

Global trends in neglected disease R&D investment

2New business models for global health R&D

3Challenges and solutions for the future

1What has been invested in neglected disease R&D?

$2.5-3.3 billion per year in neglected disease R&D between 2007 and 2011

1What has been invested in neglected disease R&D?

1Which diseases are funded?

HIV/AIDS, 1117, 34%

Malaria, 596, 18%

Tuberculosis, 584, 18%

Dengue, 249, 8%

Diarrhoeal diseases, 169,

5%

Kinetoplastids, 142, 4%

Bacterial Pneu-monia & Menin-

gitis, 107, 3%

Helminths, 90, 3%Salmonella, 48, 1%

Trachoma, 10, 0%Leprosy, 8, 0%

Buruli ulcer, 6, 0%Rheumatic fever, 1, 0%

Platform technologies, 19, 1%

Core funding, 101, 3%Unspecified, 71, 2%

Neglected disease R&D funding by disease, FY2011 (US$m)

2nd tier/semi-commercial

Top tier diseases

3rd tier/diseases

1Who is investing in neglected disease R&D?

Public sector (HICs and multilaterals);

1877; 62%

Public (LMICs); 72; 2%

Private sector (MNCs); 469; 15%

Private sector (SMEs); 56; 2%

Philanthropic; 571; 19%

Neglected disease R&D funding by sector FY2011 (US$m)

1Top funders: Average annual funding 2007-2011

1. US NIH $1,159m 2. Bill & Melinda Gates Foundation $506m

3. Pharmaceutical industry $407m 4. European Commission: Research Directorate-General $113m

5. US Agency for International Development (USAID) $83m

6. US Department of Defense (DOD) $80m

7 We l l c o m e Tr u s t $ 7 2 m 8 . U K D e p a r t m e n t f o r I n t e r n a ti o n a l D e v e l o p m e n t ( D F I D ) $ 6 9 m

2How have developing countries benefitted?

2New business models for neglected disease R&D

Product Development PartnershipsInvolved in 40% of new products for global health R&D in last decade

Innovative Developing CountriesIncreasing government investment in domestic biotech innovation

MAJOR PHARMACEUTICAL INNOVATIONS

1.MENAFRIVAC2.XPERT MTB/RIF

3.COARTEM

2How have developing countries benefitted?

MenAfriVac. 56m vaccinated since 2011

Predicted to prevent 437,000 cases in next decade

Pharmaceutical Innovation

2How have developing countries benefitted?

Coartem Dispersible Over 171m delivered to 30+ malaria endemic countries

At costs as low as $0.38 per course of treatment.

Xpert MTB/RIF. Expected to triple diagnosis of drug resistant TB.

India alone, predicted to avert 100,000 deaths/year

Coartem. Since 2001, 400+ mil treatments provided on non-profit basis by Novartis.

Estimated 1mil lives saved.

360 products in development234 in preclinical, 289 in early clinical, 42 phase III trials

THERE ARE PROMISING CANDIDATES FOR HIV/AIDS, MALARIA, TUBERCULOSIS AND DENGUE

2New business models for neglected disease R&D

3Challenges and solutions for the future Currently growing pipeline may face untimely funding cuts

R&D pipelines need reliable long-term funding

Financial pressures mean smarter funding needed: Outcome driven and flexible Aligned with product and portfolio developments Coordinated Targeted to deliver the highest health impact

3Challenges and solutions for the future

Investment in neglected disease = R&D

Improved sustainabilityin global health R&D

Enabling health impact in

developing countries

+

Collaboration & partnerships

Building Capacity in Developing Countries

Quality Research

++ +

Targeted and flexible funding

Thank you Lindsey Wu Senior Analyst, Policy Cures lwu@policycures.org